20 Jahre „Senologie“ – Entwicklungen in der Strahlentherapie

Die erste multizentrische randomisierte Therapiestudie in der Onkologie in Deutschland bei erwachsenen Patienten wurde 1984 gestartet und betraf die brusterhaltende Behandlung mit Tumorektomie und postoperativer Bestrahlung als Alternative zur Mastektomie bei pT1-pN0-Mammakarzinomen. Das Mammakarzinom war damals und ist auch heute weiterhin ein wichtiger Treiber für Diagnose- und Therapiekonzepte in der Onkologie. Das betrifft auch die Strahlentherapie.

• Literatur

• 1 Clarke M, Collins R, Darby S. et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 366: 2087-2106
• 2 Fisher B, Redmond C, Poisson R. et al. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1989; 320: 822-828
• 3 Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16 trials. Lancet 2023; 402: 1991-2003
• 4 Chesney TR, Yin JX, Rajaee N. et al. Tamoxifen with radiotherapy compared with Tamoxifen alone in elderly women with early-stage breast cancer treated with breast conserving surgery: A systematic review and meta-analysis. Radiother Oncol 2017; 123: 1-9
• 5 Kunkler IH, Williams LJ, Jack WJL. et al. Breast-Conserving Surgery with or without Irradiation in Early Breast Cancer. N Engl J Med 2023; 388: 585-594
• 6 Morgan J, Wyld L, Collins KA. et al. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). Cochrane Database Syst Rev 2014; CD004272
• 7 Valle LF, Agarwal S, Bickel KE. et al. Hypofractionated whole breast radiotherapy in breast conservation for early-stage breast cancer: a systematic review and meta-analysis of randomized trials. Breast Cancer Res Treat 2017; 162: 409-417
• 8 Haussmann J, Budach W, Corradini S. et al. Comparison of adverse events in partial- or whole breast radiotherapy: investigation of cosmesis, toxicities and quality of life in a meta-analysis of randomized trials. Radiat Oncol 2023; 18: 181
• 9 Coles CE, Griffin CL, Kirby AM. et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet 2017; 390: 1048-1060
• 10 Ho AY, Bellon JR. Overcoming Resistance – Omission of Radiotherapy for Low-Risk Breast Cancer. N Engl J Med 2023; 388: 652-653
• 11 Haussmann J, Budach W, Corradini S. et al. Whole Breast Irradiation in Comparison to Endocrine Therapy in Early Stage Breast Cancer-A Direct and Network Meta-Analysis of Published Randomized Trials. Cancers (Basel) 2023; 15: 4343
• 12 Chua BH, Link EK, Kunkler IH. et al. Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3–07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study. Lancet 2022; 400: 431-440
• 13 Coles CE, Haviland JS, Kirby AM. et al. Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial. Lancet 2023; 401: 2124-2137
• 14 Darby SC, McGale P, Taylor CW.. et al. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol 2005; 6: 557-565